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Evaluating iron sufficiency: A clearer view
Anemia is a frequent and serious complication of end- creased. Transferrin saturation values of 20 to 30% in
stage renal disease (ESRD). Since the introduction of ESRD patients are comparable to values of 13 to 20%
recombinant human erythropoietin (EPO) into clinical in normal patients. Yet, because of increased blood
practice in the 1980s, our understanding of the impor- losses and shortened red cell survival associated with
tance of iron supply for optical erythropoiesis with EPO ESRD, production of red cells has to be normal to
has increased. In the past decade we have clearly learned slightly increased to maintain hemoglobin levels higher
that anemia management can be optimized only if func- than 11 g/dL. The low total iron-binding capacity may
tional iron deficiency can be avoided [1, 2]. During func- one of the key mechanisms leading to functional iron
tional iron deficiency, erythropoietic capacity of the bone deficiency in ESRD patients since a low capaicty would
marrow to respond to epoetin is limited by iron release automatically limit uptake from tissue stores.
from storage sites and/or by a limited capacity to trans- It is therefore not surprising that functional iron defi-
port iron via transferrin [3]. The National Kidney Foun- ciency does develop and that a transferrin saturation
dation–Dialysis Outcomes Quality Initiative (NKF-DOQI) level higher than 20% or a serum ferritin level higher
guidelines advocate aggressive detection and manage- than 100 ng/mL, levels recommended by NKF-DOQI
ment of functinoal iron deficiency [4]. The presence of [4], cannot exclude the presence of functional iron defi-
functional iron deficiency is confirmed by the response ciency. Marrow iron deficiency can develop in ESRD
to a course of parenteral iron that produces either a patients at transferrin saturation values approaching
decrease in dose of EPO needed to maintain the terget 30% or ferritin levels in excess of 500 ng/mL. The only
hematocrit level or an increase in hemoglobin at the definitive way to show that functional iron deficiency is
same dose of epoetin. Analysis of these “iron restora- not present is to demonstrate no change in erythroid
tion” protocols, the most common of which administer response to additional iron administration. Our studies
1000 mg of parenteral iron over five to ten consecutive demonstrated that increasing transferrin saturation from
dialysis treatments, indicates that ferritin increases from 20 to 30% to 30 to 50% with intravenous iron dextran
a pre-treatment mean of 209 ng/mL to a post treatment in “iron-replete” hemodialysis patients resulted in a de-
mean of 447 ng/mL [3]. The latter is higher than the creased need for EPO to maintain hemoglobin of 10 to
upper limits for a normal population and is of concern 12 g/dL, that is, a higher epoetin response index (hemato-
to many physicians. crit or hemaglobin/weekly EPO dose). However, mean
These experiences underscore the limits of the cur- ferritin rose progressively to values approaching the up-
rently used iron indices to accurately indicate the iron per limits of those recommended by NKF-DOQI [1].
supply needs in EPO-treated dialysis patients. Avoid- The dilemma arising is how to provide sufficient iron
ance of iron-limited erythropoiesis anemia depends on to achieve and maintain the target hemoglobin level of
its detection. Under normal conditions, plasma trans-
11 without incurring an excessive accumulation of body
ferrin is 30 to 40% saturated with iron. Overall serum
iron [8]. The key question in the optimal use of iron toferritin levels reflect iron stores but levels are well known
manage anemia in patients with ESRD is whether thereto increase in inflammatory conditions [5]. Recently, ure-
are readily available hematopoietic parameters that canmia, per se, has been described as an inflammatory state,
detect functional iron deficiency that is superior to theperhaps explaining the poor correlation between ferritin
traditional measures, can be measured sequentially tolevels and marrow iron stores in patients on dialysis.
guide iron and indirectly EPO therapy, and yet is inex-What is frequently forgotten is that transferrin, the iron
pensive. I believe the answer is yes. In our study, contenttransport protein commonly measured as total iron bind-
of hemoglobin in reticulocytes (CHr) increased in theing capacity, is a negative acute phase reactant and is
patients maintained at the higher level transferrin satura-thus decreased in ESRD by an average of one third
tion range of 30 to 50% and the epoetin response indexcompared to subjects without kidney disease [6]. As a
increased, indicating more efficient erythropoiesis. Inresult, the total iron transport capacity of plasma is de-
this issue of Kidney Internationa, Fishbane et al extend
their previous work [9] and report findings on the use
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[10]. In this study, Group 1 patients received a “pulse” using third-generation analyzers. Our own observations
indicate that CHr can be used during maintenance ironof 1000 mg over ten treatments if they met the traditional
criteria of transferrin saturation less than 20% or ferritin therapy to adjust the parenteral iron doses (unpublished
observation). It is particularly useful in those cases inless than 100 ng/mL compared to Group 2 patients in
whom the CHr criteria of less than 29 pg hemoglobin. which ferritin exceed 500 ng/ml but TSAT is less than
15%. In many cases, the CHr indicates abundant ironThe average amount of iron administered was less than
half in the group assessed with CHr and this resulted delivery permitting downward adjustment of iron dose.
We also use Chr measurements in conjunction within lower ferritin levels but no difference in transferrin
saturation or CHr levels at study end compared to Group C-reactive protein, a sensitive marker of inflammation.
If the C-reactive protein is normal (less than 10 mg/L),1. Importantly, neither the hematocrit level nor the epoe-
tin response index differed at study end. Because hemo- we attempt to find the lowest maintenance iron dose
that maintains Chr higher than 31 pg and will maintainglobin varies independently of therapy within subjects
over time and the standard deviation of this variation that dose even if the transferrin saturation decreases to
less than 20% so long as ferritin is greater than 100 ng/is large, 0.4 to 1.4 g/dL among patients (unpublished
observation), it is difficult to use criteria of a 1 g/dL mL. If the patient has a low CHr and a high C-reactive
protein (higher than 15 mg/L), then we believe that pro-increase in hemoglobin or a 15% decrease on weekly
EPO dose within 8 weeks of the pulse dose of intrave- viding additional iron might be problematic because the
patient is either inflamed or has an infection. In thisnous iron as “absolute” in diagnosing functional iron
deficiency. However, I do believe that the nearly two- situation, we look for reversible causes of inflammation,
treat them and cut back on the iron therapy. Much offold difference in positive predictive value of diagnosing
“functional iron deficiency,” CHr versus the traditional our experience is still evolving as we search for means
of optimizing iron delivery yet avoiding excess iron. Theiron indices will stand up over the course of time.
Why should CHr be a better measure than other indi- cost of the test is significantly lower than that of the
conventional iron indices and does not require any addi-cators of iron in our patients? Assessment of iron-limited
erythropoietic activity can be done with repeated bone tional blood besides that which is routinely sent for
Coulter counter hemotology. In this era of cost-effective-marrow tests (too invasive) or sophisticated ferrokinetic
studies (too expensive and time consuming). The cells ness, further studies with CHr will no doubt define opti-
mal iron management.actively utilizing iron for the synthesis of hemoglobin
are in the bone marrow, not in the peripheral circulation.
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